AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claims 1-28 (Cancelled).

29. (Previously Presented): A method for treating cancer, the method comprising:

(a) producing activated antigen presenting cells (APC) by primary stimulation *in vitro* that exposes peripheral-blood mononuclear cells (PBMC) obtained from a biopsy to anti-CD3 antibodies;

(b) obtaining naïve PBMC comprising T cells that are naïve with respect to one or more cancer antigens;

(c) incubating the naïve PBMC in the presence of the activated PBMC to activate the naïve PBMC *in vitro*;

(d) expanding subsequently *in vitro* the population of cells (CAPRI cells), derived from the activated naïve PBMC, comprising activated T cells having specificity for the cancer antigens; and

(e) administering the CAPRI cells into a cancer patient,

wherein the cancer antigens are presented by the activated APC obtained in step (a) to the naïve T cells in the context of a MHC complex expressed on the surface of the activated APC, and

wherein the primary stimulation and/or the activation of naïve PBMC occurs in the presence of at least one cytokine selected from the group of interleukin-2 (IL-2), interleukin-4 (IL-4), and interferon γ (IFN γ).

30. (Previously Presented): The method of Claim 29, wherein the cancer is selected from the group consisting of melanoma, [[a]] breast carcinoma, colorectal carcinoma, ovarian carcinoma, glioblastoma multiform, and bowenoid papilloma.

31. (Previously Presented): The method of Claim 29, wherein administering the CAPRI cells comprises:

injecting CAPRI cells intradermally, intravenously, and/or intramuscularly.

32. (Previously Presented): The method of Claim 29, wherein administering the CAPRI cells comprises:

injecting CAPRI cells in a dosage range from about 0.5 to about 30 million cells per injection into the cancer patient.

33. (Previously Presented): The method of Claim 29, wherein administering the CAPRI cells comprises:

administering CAPRI cells into a tumour of the cancer patient, wherein the diameter of the tumour is about 0.5 cm or less.

34. (Previously Presented): The method of Claim 29, wherein the CAPRI cells are administered in conjunction with radiotherapy.

35. (Previously Presented): The method of Claim 29, wherein administering the CAPRI cells further comprises:

administering CD-3 activated T cells.

Claims 36-39 (Cancelled).

40. (Previously Presented): The method of Claim 29 further comprising:

(d') optionally incubating the CAPRI cells produced in (d) in the presence of second naïve PBMC to activate the second naïve PBMC *in vitro*; and

repeating (d),

wherein a cycle of (d') and (d) is repeated up to ten times.

41. (Previously Presented): The method of Claim 29, wherein the activated antigen presenting cells (APC) of the PMC activated in step (a) and the naïve T cells of the PBMC are derived from a single cancer patient donor.

42. (Previously Presented): The method of Claim 29, wherein the activated antigen presenting cells (APC) of the PBMC activated in step (a) and/or the naïve T cells of the PBMC are derived from an allogenic donor expressing a HLA haplotype of sufficient similarity to the HLA haplotype of the cancer patient.

43. (Previously Presented): The method of Claim 29, wherein the anti-CD3 antibodies comprise immobilized antibodies.

44. (Previously Presented): The method of Claim 29, wherein incubating the naïve PBMC in the presence of the PBMC activated in step (a) comprises:

incubating together in a ratio that ranges from about 10:1 to 1:10 when expressed as a ratio of the number of activated PBMC to the number of naïve PBMC.